Details of Disease

General Information of Disease (ID: DISJ5NW7)

Disease Name	Coccidioidomycosis
Synonyms	primary extrapulmonary coccidioidomycosis; Coccidioides immitis infectious disease; desert fever; San Joaquin valley fever; Coccidioides immitis caused disease or disorder; California disease; Valley fever; Coccidioides infection; desert rheumatism; Coccidioides immitis disease or disorder
Disease Class	1F25: Coccidioidomycosis
Definition	A fungal infection caused by Coccidioides immitis. Affected individuals usually have mild flu-like symptoms. However, pneumonia and systemic involvement with the formation of abscesses may develop as complications of the disease.
Disease Hierarchy	DISIP7GM: Primary systemic mycosis DISEM33Q: Infectious disease DISX9CEW: Parasitic infection DISJ5NW7: Coccidioidomycosis
ICD Code	ICD-11 ICD-11: 1F25
Disease Identifiers	MONDO ID MONDO_0005706 MESH ID D003047 UMLS CUI C0009186 MedGen ID 3137 HPO ID HP:0032249 Orphanet ID 228123 SNOMED CT ID 60826002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amphotericin B	DMTAJQE	Approved	Small molecular drug	[1]
Ketoconazole	DMPZI3Q	Approved	Small molecular drug	[2]
Posaconazole	DMUL5EW	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
VT-1598	DM8HBW0	Phase 1	Small molecule	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CYP51A1	TT67TDP	Strong	Biomarker	[5]
------------------------------------------------------------------------------------

References

1	Amphotericin B FDA Label
2	Ketoconazole FDA Label
3	Posaconazole FDA Label
4	ClinicalTrials.gov (NCT04208321) A Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of VT-1598 in Healthy Adult Subjects. U.S.National Institutes of Health.
5	Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs.Antimicrob Agents Chemother. 2017 Apr 24;61(5):e00111-17. doi: 10.1128/AAC.00111-17. Print 2017 May.